search
Back to results

Optiflow in Sequential Non-Invasive Ventilation (VNI-HD)

Primary Purpose

Respiratory Failure

Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Optiflow
Conventional oxygen therapy
Sponsored by
University Hospital, Bordeaux
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Respiratory Failure

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patient at least 18 years old
  • Patients affiliated to or benefiting of the French social welfare system
  • Patients with ARDS on previously healthy lung. Acute respiratory insufficiency, defined as the PaO2/FIO2 ratio less than 200 mm Hg associated with the presence of lung infiltrates on chest radiograph
  • Free and informed consent of patient
  • Hospitalized in one of involved ICU

Exclusion Criteria:

  • Existence of criteria for intubation.
  • Refusal to participate in the study.
  • Pregnancy
  • Patient under guardianship or trusteeship
  • Patients for whom a decision of non intubation has been decided.
  • Patients who have received one or several NIV session for ARDS before hospital admission
  • Home noninvasive ventilation
  • Tracheostomy
  • Hemodynamic instability
  • Hypercapnia (PaCO2>45 mm Hg).
  • left ventricular failure (cardiogenic pulmonary acute edema).
  • Ineffective coughing.
  • Recent gastric or oesophageal surgery
  • Severe ventricular rhythm disorder
  • High digestive haemorrhage
  • Lack of collaboration
  • Pernicious vomiting
  • Upper airway obstruction
  • Severe sepsis.
  • Undrained pneumothorax.

Sites / Locations

  • Service de réanimation - CH de la côte basque
  • Service de réanimation médicale - CHU de Bordeaux
  • Service de Réanimation Polyvalente - CH de Libourne
  • Service de Réanimation - CH de Perigueux
  • Service de Réanimation Polyvalente - CHU de Toulouse
  • Service de Réanimation Polyvalente - CH d'Agen
  • Réanimation polyvalente - CH d'Albi
  • Réanimation Polyvalente - CH de Mont de Marsan

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Optiflow group

Control group

Arm Description

Outcomes

Primary Outcome Measures

Average of oxygenation differences measured as the delta between PaO2/FiO2ratio at the end of the first ans second NIV session and at the end of the first and second oxygen therapy session.
Average of oxygenation differences measured as the delta between PaO2/FiO2 ratio at the end of the first NIV session and at the end of the first oxygen therapy session (according group of treatment) on the one hand and on the other hand the delta between PaO2/FiO2 ratio at the end of the second NIV session and at the end of the second oxygen thrapy session Five measurements of PaO2/FiO2 ratio are realized with arterial blood gases: at the time of inclusion, at the time of the end of first NIV session, at the time of the end of first oxygen therapy session, or at the time of rescue NIV or at the time of réintubation at the time of the end of second NIV session, at the time of the end of second oxygen therapy session These five measurements are usually realised, and they are important to optimize patient management. The primary endpoint is based on these five measurements.

Secondary Outcome Measures

comfort score dyspnea beetween the two NIV sessions
The comfort score and dyspnea will be assessed between the two NIV sessions
Incidence of serious adverse events between the two NIV sessions
Respiratory rate between the two NIV sessions
Respiratory rate to assess work of breathing between the two NIV sessions
incidence of intubation during the NIV treatment of Acute respiratory distress syndrome (ARDS)
ICU mortality
28 days survival
Hospital mortality
ICU length of stay
duration of mechanical ventilation

Full Information

First Posted
March 3, 2015
Last Updated
July 30, 2019
Sponsor
University Hospital, Bordeaux
search

1. Study Identification

Unique Protocol Identification Number
NCT02389166
Brief Title
Optiflow in Sequential Non-Invasive Ventilation
Acronym
VNI-HD
Official Title
Randomized Clinical Trial Comparing High Flow Oxygen Delivery System (Optiflow) With Oxygen Therapy Under High-concentration Mask on Oxygenation of Patients Who Receive Sequential Non-Invasive Ventilation (NIV) Sessions
Study Type
Interventional

2. Study Status

Record Verification Date
July 2019
Overall Recruitment Status
Completed
Study Start Date
June 25, 2015 (Actual)
Primary Completion Date
February 5, 2019 (Actual)
Study Completion Date
March 5, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Bordeaux

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Background : Patient with hypoxemic respiratory failure treated with NIV receive between NIV session oxygen therapy. Gaz exchange disorder with a decrease of the ratio between Partial Pressure of Arterial Oxygen (PaO2) and Inspired Fraction of Oxygen (FIO2) are noticed when NIV is stopped at the end of the session du to alveolar derecruitment Optiflow is a high flow oxygen delivery system used a heated humidifier and heated breathing circuit. In observational studies, Optiflow increase oxygenation of patients with hypoxemic respiratory failure. Oxygenation is better than under high-concentration mask and work of breathing is reduced. The aim of the study is to compare in acute hypoxemic respiratory failure, optiflow to oxygen therapy under high-concentration mask, on patients oxygenation between NIV sessions (measured as the difference between PaO2/FiO2 ratio at the beginning and at the end of the session), during the first two NIV sessions Study design : Prospective, randomized, controlled, multicentric, open clinical trial with two groups: control group with conventional clinical management, oxygen therapy and sequential used of NIV Optiflow group with high flow oxygen delivery system, conventional clinical management and sequential used of NIV for a period of 36 hours at least. Number of subjects: 100 (50 patients per group) patients admitted in intensive Care Unit for hypoxemic respiratory failure.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Respiratory Failure

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
95 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Optiflow group
Arm Type
Experimental
Arm Title
Control group
Arm Type
Active Comparator
Intervention Type
Device
Intervention Name(s)
Optiflow
Intervention Description
Patients receive high flow oxygen delivery system, Optiflow, conventional clinical management and sequential used of NIV for a period of 36 hours at least. High flow oxygen nasal therapy (Optiflow) : The flow will be set at 40l/min to 60l/min The inspired fraction of oxygen (FiO2) is the same as that defined at the end of VNI session and may be adjusted in order to obtain a SaO2 between 94% and 98%.
Intervention Type
Device
Intervention Name(s)
Conventional oxygen therapy
Intervention Description
Patients receive conventional oxygen therapy with high concentration mask, conventional clinical management, and sequential use of NIV Conventional oxygen therapy: The inspired fraction of oxygen (FiO2) is the same as that defined at the end of VNI session and may be adjusted in order to obtain a Arterial Oxygen Saturation (SaO2) between 94% and 98%.
Primary Outcome Measure Information:
Title
Average of oxygenation differences measured as the delta between PaO2/FiO2ratio at the end of the first ans second NIV session and at the end of the first and second oxygen therapy session.
Description
Average of oxygenation differences measured as the delta between PaO2/FiO2 ratio at the end of the first NIV session and at the end of the first oxygen therapy session (according group of treatment) on the one hand and on the other hand the delta between PaO2/FiO2 ratio at the end of the second NIV session and at the end of the second oxygen thrapy session Five measurements of PaO2/FiO2 ratio are realized with arterial blood gases: at the time of inclusion, at the time of the end of first NIV session, at the time of the end of first oxygen therapy session, or at the time of rescue NIV or at the time of réintubation at the time of the end of second NIV session, at the time of the end of second oxygen therapy session These five measurements are usually realised, and they are important to optimize patient management. The primary endpoint is based on these five measurements.
Time Frame
28 days
Secondary Outcome Measure Information:
Title
comfort score dyspnea beetween the two NIV sessions
Description
The comfort score and dyspnea will be assessed between the two NIV sessions
Time Frame
28 days
Title
Incidence of serious adverse events between the two NIV sessions
Time Frame
28 days
Title
Respiratory rate between the two NIV sessions
Description
Respiratory rate to assess work of breathing between the two NIV sessions
Time Frame
28 days
Title
incidence of intubation during the NIV treatment of Acute respiratory distress syndrome (ARDS)
Time Frame
28 days
Title
ICU mortality
Time Frame
28 days
Title
28 days survival
Time Frame
28 days
Title
Hospital mortality
Time Frame
28 days
Title
ICU length of stay
Time Frame
28 days
Title
duration of mechanical ventilation
Time Frame
28 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patient at least 18 years old Patients affiliated to or benefiting of the French social welfare system Patients with ARDS on previously healthy lung. Acute respiratory insufficiency, defined as the PaO2/FIO2 ratio less than 200 mm Hg associated with the presence of lung infiltrates on chest radiograph Free and informed consent of patient Hospitalized in one of involved ICU Exclusion Criteria: Existence of criteria for intubation. Refusal to participate in the study. Pregnancy Patient under guardianship or trusteeship Patients for whom a decision of non intubation has been decided. Patients who have received one or several NIV session for ARDS before hospital admission Home noninvasive ventilation Tracheostomy Hemodynamic instability Hypercapnia (PaCO2>45 mm Hg). left ventricular failure (cardiogenic pulmonary acute edema). Ineffective coughing. Recent gastric or oesophageal surgery Severe ventricular rhythm disorder High digestive haemorrhage Lack of collaboration Pernicious vomiting Upper airway obstruction Severe sepsis. Undrained pneumothorax.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Antoine BENARD, Docotor
Organizational Affiliation
University Hospital, Bordeaux
Official's Role
Study Chair
Facility Information:
Facility Name
Service de réanimation - CH de la côte basque
City
Bayonne
State/Province
Aquitaine
ZIP/Postal Code
64100
Country
France
Facility Name
Service de réanimation médicale - CHU de Bordeaux
City
Bordeaux
State/Province
Aquitaine
ZIP/Postal Code
33000
Country
France
Facility Name
Service de Réanimation Polyvalente - CH de Libourne
City
Libourne
State/Province
Aquitaine
ZIP/Postal Code
33505
Country
France
Facility Name
Service de Réanimation - CH de Perigueux
City
Perigueux
State/Province
Aquitiane
ZIP/Postal Code
24000
Country
France
Facility Name
Service de Réanimation Polyvalente - CHU de Toulouse
City
Toulouse
State/Province
Midi-pyrenees
ZIP/Postal Code
31059
Country
France
Facility Name
Service de Réanimation Polyvalente - CH d'Agen
City
Agen
ZIP/Postal Code
47923
Country
France
Facility Name
Réanimation polyvalente - CH d'Albi
City
Albi
ZIP/Postal Code
81000
Country
France
Facility Name
Réanimation Polyvalente - CH de Mont de Marsan
City
Mont de Marsan
ZIP/Postal Code
40024
Country
France

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Optiflow in Sequential Non-Invasive Ventilation

We'll reach out to this number within 24 hrs